Compare AVNW & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | SABS |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.2M | 280.2M |
| IPO Year | 2007 | N/A |
| Metric | AVNW | SABS |
|---|---|---|
| Price | $20.79 | $3.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $34.50 | $10.75 |
| AVG Volume (30 Days) | 134.2K | ★ 914.7K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $243,858,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $71.59 | ★ N/A |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $13.92 | $1.85 |
| 52 Week High | $27.02 | $6.60 |
| Indicator | AVNW | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 43.75 |
| Support Level | $20.65 | $3.42 |
| Resistance Level | $22.95 | $4.10 |
| Average True Range (ATR) | 1.13 | 0.21 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 30.06 | 17.54 |
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.